Boston Scientific Co. (BSX) Stake Raised by Bollard Group LLC

Bollard Group LLC boosted its stake in shares of Boston Scientific Co. (NYSE:BSX) by 0.1% during the first quarter, Holdings Channel reports. The institutional investor owned 35,158,562 shares of the medical equipment provider’s stock after buying an additional 26,300 shares during the period. Boston Scientific comprises 50.1% of Bollard Group LLC’s portfolio, making the stock its largest position. Bollard Group LLC’s holdings in Boston Scientific were worth $874,393,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in BSX. Quantitative Systematic Strategies LLC increased its position in shares of Boston Scientific by 29.0% in the first quarter. Quantitative Systematic Strategies LLC now owns 107,745 shares of the medical equipment provider’s stock valued at $2,680,000 after buying an additional 24,228 shares in the last quarter. DnB Asset Management AS increased its position in shares of Boston Scientific by 12.3% in the first quarter. DnB Asset Management AS now owns 137,750 shares of the medical equipment provider’s stock valued at $3,426,000 after buying an additional 15,100 shares in the last quarter. Private Wealth Partners LLC increased its position in shares of Boston Scientific by 3.4% in the first quarter. Private Wealth Partners LLC now owns 207,266 shares of the medical equipment provider’s stock valued at $5,155,000 after buying an additional 6,796 shares in the last quarter. Bank of Montreal Can increased its position in shares of Boston Scientific by 2.3% in the first quarter. Bank of Montreal Can now owns 511,136 shares of the medical equipment provider’s stock valued at $12,711,000 after buying an additional 11,611 shares in the last quarter. Finally, WCM Investment Management CA increased its position in shares of Boston Scientific by 0.7% in the first quarter. WCM Investment Management CA now owns 1,866,739 shares of the medical equipment provider’s stock valued at $46,426,000 after buying an additional 13,459 shares in the last quarter. 91.70% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Boston Scientific Co. (NYSE:BSX) traded up 0.826% on Thursday, reaching $25.015. 3,563,275 shares of the company traded hands. Boston Scientific Co. has a one year low of $19.49 and a one year high of $25.65. The firm has a 50 day moving average of $24.58 and a 200-day moving average of $23.19. The stock has a market capitalization of $34.11 billion, a PE ratio of 100.060 and a beta of 1.06.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Thursday, February 2nd. The medical equipment provider reported $0.30 EPS for the quarter, topping the consensus estimate of $0.29 by $0.01. The company earned $2.19 billion during the quarter, compared to the consensus estimate of $2.16 billion. Boston Scientific had a net margin of 4.14% and a return on equity of 23.70%. The company’s quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.26 EPS. On average, analysts anticipate that Boston Scientific Co. will post $1.25 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at http://www.wkrb13.com/markets/2065139/boston-scientific-co-bsx-stake-raised-by-bollard-group-llc.html.

BSX has been the subject of several research reports. BTIG Research restated a “hold” rating on shares of Boston Scientific in a research report on Sunday, February 5th. TheStreet upgraded shares of Boston Scientific from a “c+” rating to a “b” rating in a research report on Tuesday, January 17th. Needham & Company LLC restated a “buy” rating and issued a $29.00 price objective on shares of Boston Scientific in a research report on Thursday, February 23rd. Northland Securities restated a “positive” rating on shares of Boston Scientific in a research report on Thursday, February 23rd. Finally, Oppenheimer Holdings Inc. restated a “hold” rating on shares of Boston Scientific in a research report on Thursday, February 23rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $26.96.

In other news, EVP Keith D. Dawkins sold 80,783 shares of the firm’s stock in a transaction that occurred on Tuesday, February 7th. The shares were sold at an average price of $25.21, for a total transaction of $2,036,539.43. Following the completion of the sale, the executive vice president now owns 75,864 shares of the company’s stock, valued at approximately $1,912,531.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP John Bradley Sorenson sold 2,950 shares of the firm’s stock in a transaction that occurred on Monday, April 10th. The stock was sold at an average price of $24.66, for a total transaction of $72,747.00. Following the sale, the senior vice president now directly owns 20,980 shares of the company’s stock, valued at approximately $517,366.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 229,579 shares of company stock valued at $5,717,732. Insiders own 1.31% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

5 Day Chart for NYSE:BSX

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2065139/boston-scientific-co-bsx-stake-raised-by-bollard-group-llc.html

Receive News & Ratings for Boston Scientific Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Co. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.